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The meta-analysis by Lago et al. has brought further valuable information to a highly 
controversial topic. Indeed, several meta-analyses (listed in Lago’s paper) have already called 
into question the safety of rosiglitazone with regard to possible risks of myocardial infarction and 
cardiovascular mortality. None of the clinical trials included in these meta-analyses was designed 
to specifically evaluate the cardiovascular safety (or efficacy) of rosiglitazone, however, and the 
interim analysis of the ongoing Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of 
Glycemia in Diabetes (RECORD) trial did not report any increased cardiovascular mortality.1 
Similarly, Lago et al. found no increased risk of cardiovascular mortality associated with either 
rosiglitazone or pioglitazone when compared with placebo or a reference oral antidiabetic 
compound. In addition, there was no apparent difference between the two thiazolidinediones (RR 
= 0.91 for rosiglitazone and 1.01 for pioglitazone), although no head-to-head comparative trials 
were available. 
The risk of CHF is a well-recognized complication reported in both RECORD with 
rosiglitazone1 and PROspective pioglitAzone Clinical Trial In macroVascular Events 
(PROactive) with pioglitazone.2 In the meta-analysis of Lago et al., patients given 
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thiazolidinediones had an increased RR of CHF across a wide background of cardiovascular risk 
(overall = 1.74, pioglitazone = 1.32, and rosiglitazone = 2.41). These findings have led to a 
stronger ‘black box’ warning in the prescribing information for the thiazolidinediones. 
Nevertheless, the absence of higher cardiovascular mortality suggested that CHF in patients 
given thiazolidinediones might not carry the same high risk as is usually associated with CHF 
caused by progressive dysfunction of the left ventricle. A post-hoc analysis of the PROactive 
study confirmed that although the incidence of serious CHF was increased with pioglitazone 
versus placebo, subsequent mortality or morbidity were not increased in pioglitazone-treated 
patients with serious CHF.2 However, because of the  limited duration of observation after onset 
of CHF, longer term studies are needed for confirm that cardiovascular mortality is not an issue. 
The controversy about thiazolidinediones should lead us to reconsider the place of these 
drugs in the management of type 2 diabetes mellitus. However, in an updated algorithm that 
followed the recent thiazolidinedione controversy, experts decided not to change the guidelines 
in the absence of definitive or compelling new data: thiazolidinediones still remain as one of 
three possible choices (sulfonylurea and insulin are the other two) that should be added to 
metformin and lifestyle intervention if target HbA1c levels are not achieved. 3 Nevertheless, 
greater caution should be recommended in the use of thiazolidinediones, especially for patients at 
risk of CHF or with pre-existing CHF. For diabetic patients in whom the absolute risk of CHF is 
estimated to be low, the use of thiazolidinediones should be weighed against the risks and 
benefits of other antidiabetic medications. Caution is also advised in patients with prediabetes.4  
As highlighted by Lago et al., the true risk–benefit profile of a thiazolidinedione as compared 
with another treatment for diabetes mellitus should be assessed when all other cardiovascular 
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risk factors (including glycemia) are similar in the two treatment groups. Large, long-term, head-
to-head studies are, therefore, urgently needed to determine the comparative effects of the 




1 Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim 
analysis. N Engl J Med 357: 28–38 
2 Erdmann E et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and 
preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30: 
2773–2778 
3 Nathan DM et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a 
consensus algorithm for the initiation and adjustment of therapy: update regarding the 
thiazolidinediones. Diabetologia 51: 8–11 
4 The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) 
Trials Investigators. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with 
impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 
1096-1105. 
5 Bolen S et al. (2007) Systematic review: comparative effectiveness and safety of oral 
medications for type 2 diabetes mellitus. Ann Intern Med 147: 386–399 
 
   3
AJ Scheen is Head of the Diabetes, Nutrition and Metabolic Disorders Unit and of the Clinical 
Pharmacology Unit, Department of Medicine, the Academic Hospital of Liège, CHU Sart Tilman 
(B35), Liège, Belgium.  
 
Acknowledgments 
The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice. 
 
Competing interests 
The author has declared an association with the following companies: AstraZeneca, Eli Lilly, 
GlaxoSmithKline, Merck, Novo Nordisk, Sanofi-Aventis, and Takeda. See the article online for 
full details of the relationship. 
 
Correspondence [Au: OK?] 
Department of Medicine 
Academic Hospital of Liège 
CHU Sart Tilman (B35) 




Received 10 December 2007 
 
   4
Practice Point 
Greater caution is required in the use of thiazolidinediones for the management of type 2 
diabetes mellitus, especially in patients with a history of congestive heart failure or in those at 
high-risk of this disorder. 
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